FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4304991030> ?p ?o ?g. }

• W4304991030 endingPage "530" @default.
• W4304991030 startingPage "520" @default.
• W4304991030 abstract "Abstract Background Meningiomas, the most common primary intracranial tumors, can be separated into 3 DNA methylation groups with distinct biological drivers, clinical outcomes, and therapeutic vulnerabilities. Alternative meningioma grouping schemes using copy number variants, gene expression profiles, somatic short variants, or integrated molecular models have been proposed. These data suggest meningioma DNA methylation groups may harbor subgroups unifying contrasting theories of meningioma biology. Methods A total of 565 meningioma DNA methylation profiles from patients with comprehensive clinical follow-up at independent discovery (n = 200) or validation (n = 365) institutions were reanalyzed and classified into Merlin-intact, Immune-enriched, or Hypermitotic DNA methylation groups. RNA sequencing from the discovery (n = 200) or validation (n = 302) cohort were analyzed in the context of DNA methylation groups to identify subgroups. Biological features and clinical outcomes were analyzed across meningioma grouping schemes. Results RNA sequencing revealed differential enrichment of FOXM1 target genes across two subgroups of Hypermitotic meningiomas. Differential expression and ontology analyses showed the subgroup of Hypermitotic meningiomas without FOXM1 target gene enrichment was distinguished by gene expression programs driving macromolecular metabolism. Analysis of genetic, epigenetic, gene expression, or cellular features revealed Hypermitotic meningioma subgroups were concordant with Proliferative or Hypermetabolic meningiomas, which were previously reported alongside Merlin-intact and Immune-enriched tumors using an integrated molecular model. The addition of DNA methylation subgroups to clinical models refined the prediction of postoperative outcomes compared to the addition of DNA methylation groups. Conclusions Meningiomas can be separated into three DNA methylation groups and Hypermitotic meningiomas can be subdivided into Proliferative and Hypermetabolic subgroups, each with distinct biological and clinical features." @default.
• W4304991030 created "2022-10-14" @default.
• W4304991030 creator A5001441278 @default.
• W4304991030 creator A5004797765 @default.
• W4304991030 creator A5007540843 @default.
• W4304991030 creator A5010234110 @default.
• W4304991030 creator A5032441551 @default.
• W4304991030 creator A5032742249 @default.
• W4304991030 creator A5043828700 @default.
• W4304991030 creator A5047848562 @default.
• W4304991030 creator A5052983963 @default.
• W4304991030 creator A5055644612 @default.
• W4304991030 creator A5063617115 @default.
• W4304991030 creator A5063978061 @default.
• W4304991030 creator A5081541074 @default.
• W4304991030 creator A5082227326 @default.
• W4304991030 date "2022-10-13" @default.
• W4304991030 modified "2023-10-15" @default.
• W4304991030 title "Hypermitotic meningiomas harbor DNA methylation subgroups with distinct biological and clinical features" @default.
• W4304991030 cites W1812256879 @default.
• W4304991030 cites W2127643721 @default.
• W4304991030 cites W2148977460 @default.
• W4304991030 cites W2161289668 @default.
• W4304991030 cites W2580077891 @default.
• W4304991030 cites W2588593526 @default.
• W4304991030 cites W2598133926 @default.
• W4304991030 cites W2626440326 @default.
• W4304991030 cites W2787816121 @default.
• W4304991030 cites W2790325978 @default.
• W4304991030 cites W2794772997 @default.
• W4304991030 cites W2799347062 @default.
• W4304991030 cites W2887474968 @default.
• W4304991030 cites W2908805387 @default.
• W4304991030 cites W2944622856 @default.
• W4304991030 cites W2948500453 @default.
• W4304991030 cites W2980193786 @default.
• W4304991030 cites W2982466209 @default.
• W4304991030 cites W3044323203 @default.
• W4304991030 cites W3082090461 @default.
• W4304991030 cites W3093325233 @default.
• W4304991030 cites W3174246647 @default.
• W4304991030 cites W3194150176 @default.
• W4304991030 cites W3200626583 @default.
• W4304991030 cites W4200327950 @default.
• W4304991030 cites W4210498474 @default.
• W4304991030 cites W4226031602 @default.
• W4304991030 cites W4229449309 @default.
• W4304991030 cites W4283591755 @default.
• W4304991030 doi "https://doi.org/10.1093/neuonc/noac224" @default.
• W4304991030 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36227281" @default.
• W4304991030 hasPublicationYear "2022" @default.
• W4304991030 type Work @default.
• W4304991030 citedByCount "10" @default.
• W4304991030 countsByYear W43049910302022 @default.
• W4304991030 countsByYear W43049910302023 @default.
• W4304991030 crossrefType "journal-article" @default.
• W4304991030 hasAuthorship W4304991030A5001441278 @default.
• W4304991030 hasAuthorship W4304991030A5004797765 @default.
• W4304991030 hasAuthorship W4304991030A5007540843 @default.
• W4304991030 hasAuthorship W4304991030A5010234110 @default.
• W4304991030 hasAuthorship W4304991030A5032441551 @default.
• W4304991030 hasAuthorship W4304991030A5032742249 @default.
• W4304991030 hasAuthorship W4304991030A5043828700 @default.
• W4304991030 hasAuthorship W4304991030A5047848562 @default.
• W4304991030 hasAuthorship W4304991030A5052983963 @default.
• W4304991030 hasAuthorship W4304991030A5055644612 @default.
• W4304991030 hasAuthorship W4304991030A5063617115 @default.
• W4304991030 hasAuthorship W4304991030A5063978061 @default.
• W4304991030 hasAuthorship W4304991030A5081541074 @default.
• W4304991030 hasAuthorship W4304991030A5082227326 @default.
• W4304991030 hasConcept C104317684 @default.
• W4304991030 hasConcept C142724271 @default.
• W4304991030 hasConcept C150194340 @default.
• W4304991030 hasConcept C151730666 @default.
• W4304991030 hasConcept C190727270 @default.
• W4304991030 hasConcept C2779160599 @default.
• W4304991030 hasConcept C2779343474 @default.
• W4304991030 hasConcept C33288867 @default.
• W4304991030 hasConcept C41091548 @default.
• W4304991030 hasConcept C502942594 @default.
• W4304991030 hasConcept C54355233 @default.
• W4304991030 hasConcept C552990157 @default.
• W4304991030 hasConcept C70721500 @default.
• W4304991030 hasConcept C71924100 @default.
• W4304991030 hasConcept C86803240 @default.
• W4304991030 hasConceptScore W4304991030C104317684 @default.
• W4304991030 hasConceptScore W4304991030C142724271 @default.
• W4304991030 hasConceptScore W4304991030C150194340 @default.
• W4304991030 hasConceptScore W4304991030C151730666 @default.
• W4304991030 hasConceptScore W4304991030C190727270 @default.
• W4304991030 hasConceptScore W4304991030C2779160599 @default.
• W4304991030 hasConceptScore W4304991030C2779343474 @default.
• W4304991030 hasConceptScore W4304991030C33288867 @default.
• W4304991030 hasConceptScore W4304991030C41091548 @default.
• W4304991030 hasConceptScore W4304991030C502942594 @default.
• W4304991030 hasConceptScore W4304991030C54355233 @default.
• W4304991030 hasConceptScore W4304991030C552990157 @default.
• W4304991030 hasConceptScore W4304991030C70721500 @default.

• next